PRS
MYGN icon

Pinkerton Retirement Specialists’s Myriad Genetics MYGN Stock Holding History

Pinkerton Retirement Specialists’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-28
Closed – – 366
2016
Q4 		$0 Hold
28
– – ﹤0.01% 639
2016
Q3 		$1K Hold
28
– – ﹤0.01% 569
2016
Q2 		$1K Buy
+28
New +$973 ﹤0.01% 576

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pinkerton Retirement Specialists's MYGN Position: Q1 2017 in Review

Pinkerton Retirement Specialists sold out of Myriad Genetics (MYGN) in Q1 2017, closing a stake of 28 shares.

Pinkerton Retirement Specialists first reported a position in MYGN in Q2 2016 and held it in 3 quarters. The position peaked at $1K in Q3 2016. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2017.

  • Pinkerton Retirement Specialists reported no remaining Myriad Genetics position as of Q1 2017 after selling out during the quarter.
  • Pinkerton Retirement Specialists sold 28 Myriad Genetics shares in Q1 2017.
  • Pinkerton Retirement Specialists first reported a position in Myriad Genetics in Q2 2016 and held it in 3 quarters.
  • Pinkerton Retirement Specialists's Myriad Genetics position peaked at $1K in Q3 2016.
  • 233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2017.

Based on Pinkerton Retirement Specialists's 13F filing for Q1 2017, filed 15 May 2017.